In a phase 2 trial of 41 adults with persistent or chronic ITP, adverse events (primary outcome) were similar with weekly mezagitamab vs placebo (68% vs 69%). Secondary: platelet response by week 16 in 10 of 11 (91%) on 600 mg vs 3 of 13 (23%) on placebo.
RCTn = 41
Kuter et al. A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia